This education aims to improve psychiatrists knowledge of novel therapies for schizophrenia with a different mechanism of action than prior antipsychotics that may address long-standing limitations in efficacy and side effect burden, as well as improve psychiatrists competence related to implementation of these therapies when approved. This accredited activity will focus on improving psychiatrists knowledge and competence in the use of muscarinic receptor agonists in the treatment of schizophrenia. As a result of this educational activity, learners should be better able to: 1. Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia 2. Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia 3. Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/DKN
- Start Date: 2024-11-04 06:00:00
- End Date: 2024-11-04 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 149432.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all